| Dr Olubukola A Aina I, CRNP-ADULT | |
|
419 W Redwood St Ste 300, Baltimore, MD 21201-7003 | |
| (667) 214-1718 | |
| (410) 328-5147 |
| Full Name | Dr Olubukola A Aina I |
|---|---|
| Gender | Female |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 419 W Redwood St Ste 300, Baltimore, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881267433 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | R181982 (Maryland) | Primary |
| 363LA2200X | Nurse Practitioner - Adult Health | R181982 (Maryland) | Secondary |
| Entity Name | University Of Maryland Surgical Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962417634 PECOS PAC ID: 1658262472 Enrollment ID: O20040621000583 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
Although people infected with HIV produce many antibodies against the protein encapsulating the virus, most of these antibodies are strangely ineffective at fighting the disease. A new study suggests why some of the most common of these antibodies don't work: they target the protein in a form it takes after the virus has already invaded the cell, when it's too late, report researchers at Children's Hospital Boston and their colleagues.
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Olubukola A Aina I, CRNP-ADULT 29 S Greene St Ste 319, Baltimore, MD 21201-1504 Ph: (667) 214-1734 | Dr Olubukola A Aina I, CRNP-ADULT 419 W Redwood St Ste 300, Baltimore, MD 21201-7003 Ph: (667) 214-1718 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
Although people infected with HIV produce many antibodies against the protein encapsulating the virus, most of these antibodies are strangely ineffective at fighting the disease. A new study suggests why some of the most common of these antibodies don't work: they target the protein in a form it takes after the virus has already invaded the cell, when it's too late, report researchers at Children's Hospital Boston and their colleagues.
In this post in the Public Health Institute's "Dialogue4Health" blog, Jeffrey Meer, director of PHI's Washington-based advocacy on global health, writes that "a significant expansion of PEPFAR's existing work to combat cervical cancer" through a partnership with the George W. Bush Institute known as Pink Ribbon Red Ribbon (PRRR); a 50 percent increase in the U.S. government's "commitment to screen and treat for this type of cancer from $20 million over five years to $30 million"; and additional funding from Susan G. Komen for the Cure "to expand breast cancer awareness and prevention among the same target population of women receiving care at PEPFAR-funded HIV service sites" has allowed "the wonderfully robust PEPFAR prevention and treatment platform, considered one of the great global health achievements in recent times, to be made available to a whole new type of prevention - in this case for a non-communicable disease (NCD)."
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
One of the most comprehensive studies of the forces that have shaped patterns of human genetic variation has found strong evidence for the action of natural selection, which may help explain why certain people are at risk for a variety of conditions and others are not.
› Verified 4 days ago
Dr. Richard F. Heitmiller, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 3333 N Calvert St, Johnston Prof Bldg, Ste 610, Baltimore, MD 21218 Phone: 410-554-2063 | |
Amanpreet Singh Sherwal, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Department Of Surgery, Baltimore, MD 21218 Phone: 410-554-2734 Fax: 410-261-8085 | |
Dr. Peter W Cho, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2435 W Belvedere Ave, Suite 35, Baltimore, MD 21215 Phone: 410-601-0900 Fax: 410-601-0901 | |
Glenn Whitman, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 1800 Orleans St, Sheikh Zayed 7107 - Cardiac Surgery, Baltimore, MD 21287 Phone: 410-955-2800 Fax: 410-955-3809 | |
Dr. Eric Maier Krause, MD, JD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 419 W Redwood St Ste 300, Baltimore, MD 21201 Phone: 410-584-0428 | |
Dr. Michael Fiocco, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 201 E. University Parkway, Jpb Ll08, Baltimore, MD 21218 Phone: 410-554-6550 Fax: 410-554-6599 | |
Dr. Bradley Scott Taylor, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-5842 Fax: 410-328-2750 |